Product Description
The tACPA development candidate CIT-013 recognises the citrullinated N-terminus of histone-2A and histone-4 which are present in human NETs and are essential for NET formation. Neutrophils and aberrant NET formation contribute to the induction and propagation of inflammation. NETs are believed to be central for developing autoimmunity in human RA, SLE and other indications and are present in RA joints. NETs also play a central role in sepsis induced organ failure. (Sourced from: https://citryll.com/cit-013-development/)
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Antibody
Route of Administration: Injection
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Citryll
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Germany, Hungary, Netherlands, Poland, Spain
Active Clinical Trial Count: 1
Highest Development Phases
Phase 2: Arthritis, Rheumatoid
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CITRYLL002 | P2 |
Not yet recruiting |
Arthritis, Rheumatoid |
2027-04-01 |